Remote Monitoring with TDtect for Tardive Dyskinesia
Recruiting at 1 trial location
AS
FM
OM
Overseen ByOwen Muir, M.D.
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: iRxReminder
Must be taking: Antipsychotics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
Research Team
OM
Owen Muir, M.D.
Principal Investigator
Fermata Health
RR
Rakesh Ranjan, M.D.
Principal Investigator
Charak Research Center
Eligibility Criteria
This trial is for English-speaking individuals who have been on antipsychotic medication for at least 90 days. It's not suitable for those with Tardive Dyskinesia symptoms from Parkinson's, Tourette's, or Huntington disease. Participants must consent to the study and cannot have had a severe head injury in the past year, learning disorders that affect protocol adherence, or uncorrectable severe visual impairment.Inclusion Criteria
For the non-TD group: Speaks English fluently
You have been taking antipsychotic medication for 90 days or more.
If you have symptoms of Tardive Dyskinesia, they are not caused by Parkinson's, Tourette's syndrome, or Huntington's disease.
See 1 more
Exclusion Criteria
You had a serious head injury in the past year.
History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol
You have very poor vision that cannot be fixed with glasses or contacts.
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Remote Monitoring
Participants are remotely assessed for Tardive Dyskinesia using video recordings and interviews
4-6 weeks
Remote assessments
Follow-up
Participants are monitored for safety and effectiveness after remote monitoring
4 weeks
Treatment Details
Interventions
- TDtect
Trial Overview The trial is testing 'TDtect', a method for remotely monitoring and assessing Tardive Dyskinesia—a movement disorder caused by long-term use of certain medications. The goal is to see if this tool can effectively evaluate patients outside of a clinical setting.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Taking antipsychotic medication without Tardive DyskinesiaExperimental Treatment1 Intervention
Group II: Taking antipsychotic medication with Tardive DyskinesiaExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
iRxReminder
Lead Sponsor
Trials
1
Recruited
300+
National Institute of Mental Health (NIMH)
Collaborator
Trials
3,007
Recruited
2,852,000+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.